Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zanolimumab + CHOP (Emergent BioSolutions)
- Development stage
- Discontinued
- Lead developer
- Emergent BioSolutions
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
zanolimumab + CHOP is a combination chemo-immunotherapy regimen investigated for the treatment of CD4-positive peripheral T-cell lymphoma (PTCL). It consists of zanolimumab (formerly HuMax-CD4), a humanized IgG1 monoclonal antibody targeting the CD4 surface antigen, and the standard CHOP chemotherapy backbone (cyclophosphamide, doxorubicin, vincristine, and prednisone). Zanolimumab works by binding to CD4-expressing malignant T cells, leading to their depletion via antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), while also potentially interfering with T-cell signaling. The CHOP components provide broad cytotoxic activity by damaging DNA and disrupting mitosis. Originally developed by Genmab and later acquired by Emergent BioSolutions via TenX BioPharma, the combination was evaluated in a Phase 2 trial (NCT00893516) for newly diagnosed nodal PTCL, though development was ultimately terminated.
- Other names
- zanolimumab + cyclophosphamide + doxorubicin + vincristine + prednisoneHuMax-CD4 + CHOP
02
Targets
CD4 (T lymphocyte surface antigen)DNAGR (Glucocorticoid receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on zanolimumab + CHOP (Emergent BioSolutions).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zanolimumab + CHOP (Emergent BioSolutions).